BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27377542)

  • 21. Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial.
    Huang G; Wharton W; Travison TG; Ho MH; Gleason C; Asthana S; Bhasin S; Basaria S
    J Endocrinol Invest; 2015 Apr; 38(4):455-61. PubMed ID: 25430996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive response to testosterone replacement added to intensive lifestyle intervention in older men with obesity and hypogonadism: prespecified secondary analyses of a randomized clinical trial.
    Gregori G; Celli A; Barnouin Y; Paudyal A; Armamento-Villareal R; Napoli N; Qualls C; Villareal DT
    Am J Clin Nutr; 2021 Nov; 114(5):1590-1599. PubMed ID: 34375393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease.
    Brockenbrough AT; Dittrich MO; Page ST; Smith T; Stivelman JC; Bremner WJ
    Am J Kidney Dis; 2006 Feb; 47(2):251-62. PubMed ID: 16431254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
    Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
    Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial.
    Shah S; Bell RJ; Savage G; Goldstat R; Papalia MA; Kulkarni J; Donath S; Davis SR
    Menopause; 2006; 13(4):600-8. PubMed ID: 16837882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial.
    Dangour AD; Allen E; Elbourne D; Fasey N; Fletcher AE; Hardy P; Holder GE; Knight R; Letley L; Richards M; Uauy R
    Am J Clin Nutr; 2010 Jun; 91(6):1725-32. PubMed ID: 20410089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
    Parvanova A; Trillini M; Podestà MA; Iliev IP; Ruggiero B; Abbate M; Perna A; Peraro F; Diadei O; Rubis N; Gaspari F; Carrara F; Stucchi N; Belviso A; Bossi AC; Trevisan R; Remuzzi G; de Borst M; Ruggenenti P;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):27-40. PubMed ID: 29104158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
    Kantrowitz JT; Woods SW; Petkova E; Cornblatt B; Corcoran CM; Chen H; Silipo G; Javitt DC
    Lancet Psychiatry; 2015 May; 2(5):403-412. PubMed ID: 26360284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
    Hanney M; Prasher V; Williams N; Jones EL; Aarsland D; Corbett A; Lawrence D; Yu LM; Tyrer S; Francis PT; Johnson T; Bullock R; Ballard C;
    Lancet; 2012 Feb; 379(9815):528-36. PubMed ID: 22236802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
    Howell SJ; Radford JA; Adams JE; Smets EM; Warburton R; Shalet SM
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Cognition Support Formula® on cognitive function in older adults with subjective cognitive impairment: a protocol for a 26-week, randomised, double-blind, placebo-controlled trial.
    Cave AE; Chang DH; Münch GW; Steiner GZ
    Trials; 2019 Jun; 20(1):345. PubMed ID: 31182153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial.
    Durga J; van Boxtel MP; Schouten EG; Kok FJ; Jolles J; Katan MB; Verhoef P
    Lancet; 2007 Jan; 369(9557):208-16. PubMed ID: 17240287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    Budoff MJ; Ellenberg SS; Lewis CE; Mohler ER; Wenger NK; Bhasin S; Barrett-Connor E; Swerdloff RS; Stephens-Shields A; Cauley JA; Crandall JP; Cunningham GR; Ensrud KE; Gill TM; Matsumoto AM; Molitch ME; Nakanishi R; Nezarat N; Matsumoto S; Hou X; Basaria S; Diem SJ; Wang C; Cifelli D; Snyder PJ
    JAMA; 2017 Feb; 317(7):708-716. PubMed ID: 28241355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
    Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.